Surviving the year: Predictors of mortality in conservative kidney management.

IF 2 Q1 MEDICINE, GENERAL & INTERNAL
Swee Ping Teh, Boon Cheok Lai, Ivan Wei Zhen Lee, Shashidhar Baikunje, Sye Nee Tan, Lee Ying Yeoh
{"title":"Surviving the year: Predictors of mortality in conservative kidney management.","authors":"Swee Ping Teh, Boon Cheok Lai, Ivan Wei Zhen Lee, Shashidhar Baikunje, Sye Nee Tan, Lee Ying Yeoh","doi":"10.47102/annals-acadmedsg.2025168","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Conservative kidney management (CKM) is a recognised treatment option for selected patients with chronic kidney disease stage 5 (CKD G5), but prognostic indicators for mortality and optimal timing for palliative care transition remain uncertain.</p><p><strong>Method: </strong>This is a single-centre, prospective cohort study of CKD G5 patients who opted for CKM, conducted between April 2021 and September 2024, with longitudinal monitoring of Edmonton Symptom Assessment System Revised: Renal; Palliative Perfor-mance Scale (PPS); Resources Utilisation Group.Activities of Daily Living (RUG-ADL) scale; Clinical Frailty Score; Karnofsky Performance Score; and clinical and laboratory data. Primary outcomes included identifying baseline mortality predictors and validating the PPS for survival estimation. Cox proportional hazards models were used to identify independent predictors of mortality.</p><p><strong>Results: </strong>Among 109 patients (mean age 79.8±7.3 years, 64.2% female), 62 (56.9%) died during follow-up. Multivariate analysis identified baseline estimated glomerular filtration rate (eGFR) (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.08.1.68, P<0.01) and serum albumin (HR 1.24, 95% CI 1.08.1.43, P<0.01) as predictors of 1-year mortality. Median survival varied by eGFR: 3.0 months (95% CI 0.6.2) for eGFR .5 mL/min/1.73 m<sup>2</sup>, 13.0 months (95% CI 9.1.16.9) for eGFR 6.10 mL/ min/1.73 m<sup>2</sup>, and 20.0 months (95% CI 16.5.23.5) for eGFR >10 mL/min/1.73 m<sup>2</sup> (P<0.01). Subsequent PPS correlated strongly with survival, with median survival of 1.8 months for PPS <50, 5.3 months for PPS 50.60, and 7.9 months for PPS 70.80 (P=0.03).</p><p><strong>Conclusion: </strong>Baseline eGFR and serum albumin predict 1-year mortality in CKM patients. PPS offers a practical tool for identifying patients requiring palliative care transition, supporting personalised care pathways and timely integration of palliative care.</p>","PeriodicalId":502093,"journal":{"name":"Annals of the Academy of Medicine, Singapore","volume":"54 9","pages":"524-530"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Academy of Medicine, Singapore","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47102/annals-acadmedsg.2025168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Conservative kidney management (CKM) is a recognised treatment option for selected patients with chronic kidney disease stage 5 (CKD G5), but prognostic indicators for mortality and optimal timing for palliative care transition remain uncertain.

Method: This is a single-centre, prospective cohort study of CKD G5 patients who opted for CKM, conducted between April 2021 and September 2024, with longitudinal monitoring of Edmonton Symptom Assessment System Revised: Renal; Palliative Perfor-mance Scale (PPS); Resources Utilisation Group.Activities of Daily Living (RUG-ADL) scale; Clinical Frailty Score; Karnofsky Performance Score; and clinical and laboratory data. Primary outcomes included identifying baseline mortality predictors and validating the PPS for survival estimation. Cox proportional hazards models were used to identify independent predictors of mortality.

Results: Among 109 patients (mean age 79.8±7.3 years, 64.2% female), 62 (56.9%) died during follow-up. Multivariate analysis identified baseline estimated glomerular filtration rate (eGFR) (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.08.1.68, P<0.01) and serum albumin (HR 1.24, 95% CI 1.08.1.43, P<0.01) as predictors of 1-year mortality. Median survival varied by eGFR: 3.0 months (95% CI 0.6.2) for eGFR .5 mL/min/1.73 m2, 13.0 months (95% CI 9.1.16.9) for eGFR 6.10 mL/ min/1.73 m2, and 20.0 months (95% CI 16.5.23.5) for eGFR >10 mL/min/1.73 m2 (P<0.01). Subsequent PPS correlated strongly with survival, with median survival of 1.8 months for PPS <50, 5.3 months for PPS 50.60, and 7.9 months for PPS 70.80 (P=0.03).

Conclusion: Baseline eGFR and serum albumin predict 1-year mortality in CKM patients. PPS offers a practical tool for identifying patients requiring palliative care transition, supporting personalised care pathways and timely integration of palliative care.

存活一年:保守肾管理死亡率的预测因素。
保守肾管理(CKM)是选定的慢性肾病5期(CKD G5)患者公认的治疗选择,但死亡率的预后指标和姑息治疗过渡的最佳时机仍然不确定。方法:这是一项针对选择CKM的CKD G5患者的单中心前瞻性队列研究,于2021年4月至2024年9月进行,纵向监测埃德蒙顿症状评估系统修订:肾;姑息治疗表现量表(PPS);资源利用组。日常生活活动(RUG-ADL)量表;临床虚弱评分;卡诺夫斯基表演分数;以及临床和实验室数据。主要结果包括确定基线死亡率预测因子和验证PPS用于生存估计。Cox比例风险模型用于确定死亡率的独立预测因子。结果:109例患者(平均年龄79.8±7.3岁,女性占64.2%),随访期间死亡62例(56.9%)。多因素分析确定基线估计肾小球滤过率(eGFR)(风险比[HR] 1.32, 95%可信区间[CI] 1.08.1.68, P2, eGFR 6.10 mL/min/1.73 m2时13.0个月(95% CI 9.1.16.9), eGFR 10 mL/min/1.73 m2时20.0个月(95% CI 16.5.23.5)。结论:基线eGFR和血清白蛋白预测CKM患者1年死亡率。PPS提供了一个实用的工具,用于识别需要姑息治疗过渡的患者,支持个性化护理途径和及时整合姑息治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信